
WHAT IS CLAIMED IS:

1. A method of treating cancer in a patient, comprising administering to said patient:

(i) Compound 1, having the structure:



Compound 1;

or a pharmaceutically acceptable salt thereof; and

(ii) an antibody, or an antigen-binding fragment thereof, that binds to human PD-1, wherein the antibody comprises (ii-1) a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3; and (ii-2) a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3; wherein:

(a) the VH CDR1 comprises the amino acid sequence SYWMN (**SEQ ID NO:6**);

(b) the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (**SEQ ID NO:7**);

(c) the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (**SEQ ID NO:8**);

(d) the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (**SEQ ID NO:9**);

(e) the VL CDR2 comprises the amino acid sequence AASNQGS (**SEQ ID NO:10**); and

(f) the VL CDR3 comprises the amino acid sequence QQSKEVPYT (**SEQ ID NO:11**).

2. The method of claim 1, wherein Compound 1 and the antibody are administered simultaneously.

3. The method of claim 1, wherein Compound 1 and the antibody are administered sequentially.

4. The method of claim 1, wherein Compound 1 is administered orally.

5. The method of any one of claims 1-4, wherein the antibody or antigen-binding fragment is administered via intravenous administration.

6. The method of any one of claims 1-5, wherein the antibody or antigen-binding fragment is administered at a dose of 375 mg once every 3 weeks.

7. The method of any one of claims 1-5, wherein the antibody or antigen-binding fragment is administered at a dose of 500 mg once every 4 weeks.

8. The method of any one of claims 1-5, wherein the antibody or antigen-binding fragment is administered at a dose of 750 mg once every 4 weeks.

9. The method of any one of claims 1-8, wherein the VH domain comprises the amino acid sequence set forth in **SEQ ID NO:4**.

10. The method of any one of claims 1-9, wherein the VL domain comprises the amino acid sequence set forth in **SEQ ID NO:5**.

11. The method of any one of claims 1-8, wherein the VH domain comprises the amino acid sequence set forth in **SEQ ID NO:4** and the VL domain comprises the amino acid sequence set forth in **SEQ ID NO:5**.

12. The method of any one of claims 1-11, wherein:

(a) the antibody comprises an Fc Region and a Hinge Domain;

(b) the Fc Region and the Hinge Domain are of the IgG4 type; and

(c) the Hinge Domain comprises a stabilizing mutation.

13. The method of any one of claims 1-12, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in **SEQ ID NO:2**.

14. The method of any one of claims 1-13, wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in **SEQ ID NO:3**.

15. The method of any one of claims 1-12, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in **SEQ ID NO:2** and the light chain comprises the amino acid sequence set forth in **SEQ ID NO:3**.

16. The method of any one of claims 1-11, wherein the antibody comprises an Fc Region that is of the IgG1 type.

17. The method of any one of claims 1-12 and 16, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in **SEQ ID NO:13**.

18. The method of any one of claims 1-12 and 16, wherein the antibody comprises a light chain and a heavy chain, wherein the heavy chain comprises the amino acid sequence set forth in **SEQ ID NO:13** and the light chain comprises the amino acid sequence set forth in **SEQ ID NO:3**.

19. The method of any one of claims 1-18, wherein the antibody is a humanized antibody.

20. The method of any one of claims 1-19, wherein the cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, anal cancer, Merkel cell carcinoma, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.

21. The method of any one of claims 1-19, wherein the cancer is selected from sarcoma, head and neck cancer, melanoma, and non-small cell lung cancer.